Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.052 AUD | -10.34% | -11.86% | -16.13% |
Mar. 25 | Transcript : Prescient Therapeutics Limited - Special Call | |
Feb. 23 | Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 1.89M 1.24M | Sales 2023 | 2.43M 1.59M | Capitalization | 65.23M 42.65M |
---|---|---|---|---|---|
Net income 2022 | -5M -3.27M | Net income 2023 | -7M -4.58M | EV / Sales 2022 | 47.2 x |
Net cash position 2022 | 12.28M 8.03M | Net cash position 2023 | 21.92M 14.33M | EV / Sales 2023 | 17.8 x |
P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-8.41
x | Employees | 3 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.49% |
Latest transcript on Prescient Therapeutics Limited
1 day | -10.34% | ||
1 week | -11.86% | ||
Current month | -5.45% | ||
3 months | -8.77% | ||
6 months | -8.77% | ||
Current year | -16.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 14-11-27 | |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Engle
CHM | Chairman | 69 | 14-11-27 |
James Campbell
BRD | Director/Board Member | - | 14-11-27 |
Ellen Feigal
BRD | Director/Board Member | 69 | 23-05-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.052 | -10.34% | 1 126 758 |
24-04-24 | 0.058 | +1.75% | 831,801 |
24-04-23 | 0.057 | -3.39% | 1,352,607 |
24-04-22 | 0.059 | 0.00% | 725,004 |
24-04-19 | 0.059 | -4.84% | 531,255 |
Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-16.13% | 30.38M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+46.85% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- PTX Stock